Clinical Trial Update: Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab in combination with ixazomib citrate and dexamethasone for relapsed multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Ixazomib citrate (Ixazomib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2022-11-14